SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila’s arm gets tentative approval from USFDA for Pregabalin Capsules

01 Dec 2017 Evaluate

Cadila Healthcare’s wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Pregabalin Capsules in strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The drug is used for management of certain kinds of seizures, neuropathic pain (nerve pain) and fibromyalgia. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 175 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

939.55 -3.00 (-0.32%)
20-Apr-2026 14:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.40
Dr. Reddys Lab 1234.00
Cipla 1233.00
Zydus Lifesciences 939.55
Lupin 2330.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×